Marc GuntherHow Yale researchers helped create the ketamine industry — and their own psychedelics startup.The clinical trial that set the stage for today’s fast-growing ketamine industry runs just three pages long and involved only eight…Sep 21, 2023Sep 21, 2023
Marc GuntherThe psychedelics movement has come a long way in a hurryA report from MAPS Psychedelic Science 2023 conference.Jun 27, 20232Jun 27, 20232
Marc GuntherWhy I invested in TactogenMDMA is a wonderful medicine. This startup company wants to make it even better.May 2, 20231May 2, 20231
Marc GuntherPsychedelics startup Gilgamesh has no interest in psilocybin or LSDIt’s developing new compounds and attracting investorsMar 9, 20232Mar 9, 20232
Marc GuntherA psychedelics startup has a big vision. Investors aren’t buying it.Awakn Life Science’s ketamine therapy for alcohol use disorder is promising. Will it be profitable?Jan 20, 20231Jan 20, 20231
Marc GuntherRoland Griffiths, and his legacyA Johns Hopkins professor and leading researcher of psychedelics faces his death and invites others to carry on his work.Jan 12, 20231Jan 12, 20231
Marc GuntherAt Horizons 2022, a cloudy outlook for psychedelicsScientific research and drug reform are moving forward. The business of psychedelic medicines? Not so much.Oct 17, 20221Oct 17, 20221
Marc GuntherChurches are providing psychedelics to their followers. Is that legal?Some lawyers say plant-medicine churches are exercising their freedom of religion. Others advise caution. It’s complicated.Oct 4, 2022Oct 4, 2022
Marc GuntherBeyond Michael Pollan: Where to learn more about psychedelics.A guide for the curious to the best books, writers, filmmakers and talkers about psychedelicsSep 19, 20222Sep 19, 20222
Marc GuntherCody Swift’s big bets are paying offHis philanthropy is helping to drive the psychedelic renaissanceSep 12, 2022Sep 12, 2022